A separate Alessi et al. study reported better OS in NSCLC patients with SMARCA4 WT (N = 1327) vs. SMARCA4-mutated patients (N = 163): SMARCA4 WT 25.0 months vs. SMARCA4-mutated 15.6 months (HR: 0.064; p < 0.001) [21]. The gene discussed is SMARCA4; the disease is non-small cell lung carcinoma.